Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
Lyell Immunopharma announced updated safety and translational data from their Phase 1/2 trial of rondecabtagene autoleucel (ronde-cel) CAR T-cell therapy in relapsed or refractory large B-cell lymphoma patients. The therapy showed manageable safety with no Grade ≥3 cytokine release syndrome (CRS) and low Grade ≥3 neurotoxicity (ICANS). Translationa…